On June 7, 2022, the Federal Trade Commission (FTC) unanimously voted to initiate a study into how business practices employed by some pharmacy benefit managers (PBMs) may impact.
To embed, copy and paste the code into your website or blog:
The U.S. House of Representatives is considering dueling proposals related to drug pricing under Medicaid and Medicare, including the Republican-led H.R. 19, the “Lower Costs, More Cures Act of 2021” and a reintroduced version of the Democrat-led “Elijah E. Cummings Lower Drug Costs Now Act,” originally introduced in 2019 (and hereinafter referred to) as H.R. 3. Although the bills diverge in various material respects, both would implement sweeping changes related to drug coverage and price reporting. At the same time that the House considers these proposals, Senate Democrats are urging President Biden to include major drug pricing legislation in the second phase of his infrastructure plan. The White House has been silent to date on whether drug pricing will be addressed in the next proposed infrastructure package.